arrow
É

Élie Haddad

université de montréal
H指数:67
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC)

免疫监测和表型评估对临床轨迹的影响(IMPACT),用于原发性免疫缺陷治疗联盟(PIDTC)中免疫先天性错误疾病患者

2026-08-010
PRE
Clinical spectrum of Wiskott-Aldrich syndrome carriers: Self-reported survey of 193 carriers

Wiskott-Aldrich综合征携带者的临床谱:193名携带者的自我报告调查

2025-12-170
PRE
Prime Editing for p47phox-Deficient Chronic Granulomatous Disease

Gori, J.L.; Haddad, E.; Frangoul, H.; Kohn, D.B.; Morris, E.C.; Martin, B.N.; Deary, B.A.; Nickerson, M.; Scholz, R.L.; Fernandez, I.; et al. 基因组编辑技术用于p47phox缺陷型慢性肉芽肿病。N. Engl. J. Med. 2025. [Google Scholar] [CrossRef] [PubMed]

2025-12-010
PRE
Umbilical Cord Blood Transplantation Provides an Alternative for Patients with Chronic Granulomatous Disease Lacking HLA-Matched Donors: a PIDTC Report

脐带血移植为缺乏HLA匹配供体的慢性肉芽肿病患者提供了替代方案:一份PIDTC报告

2025-10-020
PRE
Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019-Associated Hospitalization: A Population-Based Cohort Study in the Province of Québec, Canada

奈玛特韦-利托那韦在预防2019冠状病毒病相关住院中的真实世界有效性:加拿大魁北克省一项基于人群的队列研究

2025-10-010
PRE
Pediatric COVID-19 severity by SARS-CoV-2 lineage and vaccine status in Canada: an IMPACT study
2025-01-240
PRE
Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings

自然杀伤细胞杀伤治疗诱导剂 (ThINKK): 异基因造血干细胞移植安全性和有效性的临床前评估

2024-05-152
OAAI
Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study
2024-05-013
PRE
The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants
Science
IF45.8
2024-01-010
OA
Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
2024-01-014
OAAI
Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease
2023-12-018
OAAI